A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0783499B1 Benzofuran derivatives as tachykinin antagonists
10/23/2002	EP0719141B1 Novel use of dexmedetomidine
10/23/2002	EP0717991B1 Neurotropic agent and process for producing it
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376154A Piperidine derivatives as serotonine reuptake inhibitors
10/23/2002	CN1376153A Amide compounds
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376073A Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation
10/23/2002	CN1376065A Compositions having improved stability
10/23/2002	CN1376058A Oral controlled release formulations
10/23/2002	CN1376036A Metal-containing compositions, preparations and uses
10/23/2002	CN1375494A Iso-indolo-indolone compound, their preparation methods and drug compositions comprising the same
10/23/2002	CN1375490A Novel indeno indolone compound, its preparation method and drug composition comprising the same
10/23/2002	CN1375299A Hemiplegia-treating Chinese medicine and its prepn.
10/23/2002	CN1375292A Mixed snuff prepn. for reducing side effect of Apomorphinum
10/23/2002	CN1375286A Sesquiterpene component with nerve calming soporific function and its medicinal use
10/23/2002	CN1093130C Substituted pyrido 6,6-bicyclic derivatives
10/23/2002	CN1093127C 哌嗪衍生物 Piperazine derivatives
10/23/2002	CN1093123C Aralkyl and aralkylidene heterocyclic lactams and imides
10/23/2002	CN1093122C Piperazine derivatives as 5-HTIA antagonists
10/23/2002	CN1092980C Medicine for curing tooth-ache
10/23/2002	CN1092973C Use of mastic or mastic lipophilia extract in preparation of drug for treatment of alzheimer's disease
10/23/2002	CN1092958C Melatonic derivatives for use in treating sleep disorders
10/23/2002	CN1092956C Sustained release drug formulation containing a tramadol salt
10/23/2002	CN1092939C Composition for suppressing withdrawal symptoms and craving for alcohol in alcoholis and preventing abuse of alcohol in healthy subjects
10/23/2002	CA2381630A1 Method for preventing dyskinesias
10/22/2002	WO2001091753A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine
10/22/2002	US6469213 Tramadol, salts thereof and process for their preparation
10/22/2002	US6469174 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
10/22/2002	US6469168 For the treatment of central nervous system disorders, especially anxiety
10/22/2002	US6469166 Crf receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders
10/22/2002	US6469069 Propofol composition containing sulfite
10/22/2002	US6469066 Treating burns with one or more of acetic acid, vinegar and citric acid for prevention of delayed hyperalgesia
10/22/2002	US6469064 Treating depression and affective disorders, such as obsessive compulsive disorder in a patient by administering to the patient an effective amount of flavoxamine ester derivatives
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469055 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469041 Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469025 For the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role; inhibiting the binding of alpha 4 integrins to their ligands
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6469019 Prevention/treatment of motor neuron diseases; amyotrophic lateral sclerosis
10/22/2002	US6469018 Compounds
10/22/2002	US6469011 Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
10/22/2002	US6469007 P-substituted-n-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-n-pyridin-2-yl-benzamide,
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6468999 Treating anxiety, depression and other central nervous system disorders in humans and animals
10/22/2002	US6468997 Desmethylolanzapine compositions and methods
10/22/2002	US6468990 Method of inhibiting binding of nerve growth factor to p75 NTR receptor
10/22/2002	US6468978 Conjugate comprising 1 to 4 moieties covalently bound to polypeptide comprising hedgehog n-terminal domain, each being polypeptide containing 10 to 30 hydrophobic amino acids or positively charged amino acids forming transmembrane helices
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468973 Method in the treatment of schizophrenia
10/22/2002	US6468794 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
10/22/2002	US6468791 Chromosone 1 gene and gene products related to Alzheimer's disease
10/22/2002	US6468756 Methods of identifying compounds that bind to SNORF25 receptors
10/22/2002	CA2406976A1 Active substance combination containing an opioid having a fentanyl-type structure and ketamine
10/22/2002	CA2291129C Method for the preparation of citalopram
10/22/2002	CA2212904C The activity-inhibitor and activity-potentiator for glutamic acid in the brain
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/22/2002	CA2073084C The use of sulphur-containing carboxylic acids to combat physiologically-induced excitatory disorders and diseases related thereto as well as allergic diseases and also the preparation of corresponding medicaments
10/20/2002	CA2382326A1 Therapeutic use of selective pde10 inhibitors
10/17/2002	WO2002082075A2 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081690A1 Novel protein, dna thereof and use of the same
10/17/2002	WO2002081636A2 Protein modification and maintenance molecules
10/17/2002	WO2002081508A2 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	WO2002081505A2 Peptide for the diagnosis and therapy of alzheimer's disease
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081474A1 Triazolophthalazine / quinoline / isoquinoline derivatives which are ligands for gaba-a receptors containing the alpha 5 subtype
10/17/2002	WO2002081471A1 Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
10/17/2002	WO2002081464A1 Benzoaxathiepin derivatives and their use as medicines
10/17/2002	WO2002081461A1 Piperazine derivatives as tachykinin antagonists
10/17/2002	WO2002081457A1 `1,4!-diazepane-1-carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081435A1 Sulphones which modulate the action of gamma secretase
10/17/2002	WO2002081433A1 Sulphones which modulate the action of gamma secretase
10/17/2002	WO2002081430A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	WO2002081414A2 Supercritical hydrogenation
10/17/2002	WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080976A2 Hsa-free formulations of interferon-beta
10/17/2002	WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002	WO2002080960A2 Treatment of neuropathologies associated with expression of tnf-alpha
10/17/2002	WO2002080957A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/17/2002	WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002	WO2002080945A2 Methods for treating the inflammatory component of a brain disorder
10/17/2002	WO2002080942A1 Pharmaceutical composition comprising copper, salicyclic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection
10/17/2002	WO2002080941A1 Compositions for preparing external carbon dioxide agents
10/17/2002	WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002	WO2002080928A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080919A1 Therapeutic compounds and methods
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002	WO2002080905A1 Kappa opiate agonists for the treatment of bladder diseases

1 ... 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 ... 1833